One in five (19%) firms over 200 workers covers GLP-1 agonists for weight loss with more coverage among larger firms One-in-five (19%) firms with 200 or more workers, including 43% of firms with 5,000 or more workers, cover GLP-1 drugs for weight loss in their largest health plan in 2025
Phase 3 results published in December 2025 from the TRIUMPH-4 trial a double-blind, placebo-controlled study in 445 adults with obesity or overweight and knee osteoarthritis showed the 12mg dose producing an average of 28.7% body weight reduction at 68 weeks
Biostimulators address volumetric loss by stimulating deep collagen production
Additionally, untreated dry mouth can lead to bad breath, oral infections, oral sores, sensitive teeth, and difficulty in speaking and swallowing
At the security checkpoint Place your cooler bag in a separate bin on the conveyor
The primary role of GLP-1 therapy in weight management is to assist patients in achieving and maintaining metabolic balance